Triferic Avnu

  • Anemias

Triferic Avnu Generic Name & Formulations

General Description

Elemental iron (III) (as ferric pyrophosphate citrate) 1.5mg/mL; soln for IV infusion.

Pharmacological Class


See Also

How Supplied

Ampules (5mL)—5, 40; (50mL)—4, 24; Single-dose ampules (4.5mL)—10, 40; Packets— 1, 100


Generic Availability


Triferic Avnu Indications


Iron replacement to maintain hemoglobin in adults with hemodialysis-dependent chronic kidney disease (HDD-CKD).

Limitations of Use

Not for use in patients receiving peritoneal dialysis. Not studied in patients receiving home hemodialysis.

Triferic Avnu Dosage and Administration


Administer as a slow continuous IV infusion over 3–4hrs via pre- or post-dialyzer infusion line, or a separate connection to the venous blood line. Give 6.75mg (undiluted) at each dialysis procedure.


Not established.

Triferic Avnu Contraindications

Not Applicable

Triferic Avnu Boxed Warnings

Not Applicable

Triferic Avnu Warnings/Precautions


Monitor for hypersensitivity reactions during and after hemodialysis until clinically stable. Have personnel and resuscitative equipment immediately available. Determine iron status on pre-dialysis blood samples. Pregnancy. Advise females of reproductive potential to use effective contraception during and for at least 2weeks after therapy completion. Nursing mothers.

Triferic Avnu Pharmacokinetics

See Literature

Triferic Avnu Interactions

Triferic Avnu Adverse Reactions

Adverse Reactions

Headache, peripheral edema, asthenia, AV fistula thrombosis, urinary tract infection, AV fistula site hemorrhage, pyrexia, fatigue, procedural hypotension, muscle spasms, pain in extremity, back pain, dyspnea.

Triferic Avnu Clinical Trials

See Literature

Triferic Avnu Note

Not Applicable

Triferic Avnu Patient Counseling

See Literature